Anthera receives Nasdaq letter saying recent 10-Q fell below $10M minimum
According to a regulatory filing, on May 15, 2017, Anthera Pharmaceuticals received a letter from Nasdaq informing the company that its most recent Form 10-Q for the period ended March 31, 2017 reported stockholders' equity fell below the minimum of $10M for continued inclusion under Listing Rule 5450b1A. The letter stated that the company may submit a plan to regain compliance to Nasdaq within 45 days of receipt of the letter. The company intends to do so. If the plan is accepted, Nasdaq can grant an extension of up to 180 days for the company to regain compliance. The letter has no immediate effect on the listing of the company's common stock.